Novavax, Inc. (NASDAQ:NVAX) Receives Average Rating of “Hold” from Analysts

Novavax, Inc. (NASDAQ:NVAX) has received an average rating of “Hold” from the six analysts that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have given a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $17.83.

A number of research firms have recently commented on NVAX. HC Wainwright reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Novavax in a research note on Tuesday, December 10th. Jefferies Financial Group reduced their price objective on shares of Novavax from $31.00 to $25.00 and set a “buy” rating on the stock in a research note on Wednesday, October 16th. Finally, B. Riley reaffirmed a “buy” rating and issued a $26.00 price objective (up from $23.00) on shares of Novavax in a research note on Thursday, October 10th.

Novavax Price Performance

NVAX opened at $8.83 on Friday. Novavax has a fifty-two week low of $3.53 and a fifty-two week high of $23.86. The firm has a market capitalization of $1.41 billion, a price-to-earnings ratio of -3.91 and a beta of 2.07. The company’s 50 day moving average price is $8.63 and its two-hundred day moving average price is $10.97.

Novavax (NASDAQ:NVAX) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.07. The business had revenue of $84.51 million for the quarter, compared to the consensus estimate of $65.80 million. During the same period in the previous year, the firm earned ($1.26) earnings per share. The company’s revenue was down 54.8% compared to the same quarter last year. As a group, equities research analysts predict that Novavax will post -1.31 EPS for the current year.

Insider Buying and Selling

In other Novavax news, Director James F. Young sold 5,400 shares of the company’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $8.00, for a total transaction of $43,200.00. Following the transaction, the director now owns 51,760 shares in the company, valued at approximately $414,080. This represents a 9.45 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Rachel K. King sold 4,150 shares of the company’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $9.02, for a total transaction of $37,433.00. Following the transaction, the director now owns 14,770 shares in the company, valued at approximately $133,225.40. The trade was a 21.93 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 14,150 shares of company stock valued at $119,641 over the last ninety days. 1.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. State Street Corp raised its holdings in shares of Novavax by 26.7% in the third quarter. State Street Corp now owns 7,687,951 shares of the biopharmaceutical company’s stock valued at $97,099,000 after purchasing an additional 1,621,772 shares during the last quarter. Shah Capital Management raised its holdings in shares of Novavax by 13.6% in the fourth quarter. Shah Capital Management now owns 11,148,846 shares of the biopharmaceutical company’s stock valued at $89,637,000 after purchasing an additional 1,333,305 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Novavax in the second quarter valued at about $14,055,000. SG Americas Securities LLC raised its holdings in shares of Novavax by 940.7% in the third quarter. SG Americas Securities LLC now owns 1,154,276 shares of the biopharmaceutical company’s stock valued at $14,579,000 after purchasing an additional 1,043,363 shares during the last quarter. Finally, Two Sigma Advisers LP raised its holdings in shares of Novavax by 48.9% in the third quarter. Two Sigma Advisers LP now owns 1,999,400 shares of the biopharmaceutical company’s stock valued at $25,252,000 after purchasing an additional 656,900 shares during the last quarter. Institutional investors and hedge funds own 53.04% of the company’s stock.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.